biolitec AG
biolitec AG: increases group revenue to Euro 8.9 million in the first quarter of the fiscal year 2011/2012
biolitec AG / Key word(s): Quarter Results 15.06.2012 14:48 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG increases group revenue to Euro 8.9 million in the first quarter of the fiscal year 2011/2012 Jena, June 15th, 2012 - biolitec AG, Jena, listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409), achieved a group revenue of Euro 8.97 million in the first quarter of the fiscal year 2011/2012. Thereby, the revenue was Euro 1.4 million above the same period in the previous year. The revenue growth of more than 19% is attributable to the growing demand for biolitec's mainstays of sales, the LIFE(TM) laser treatment of benign prostate hyperplasia (BPH) and the endoluminal laser treatment of veins (ELVeS(TM)). The gross profit amounted to Euro 5.8 million (previous year: Euro 5.2 million) and EBIT amounted to Euro 0.97 million (previous year: Euro 0.74 million). R&D expenditures for the first three months of the fiscal year 2011/2012 of Euro 0.8 million (about 9% of sales) compared to the previous year (Euro 0.6 million) remain on the required level to ensure the company's long term growth and profitability. Sales costs were reduced to Euro 2.3 million (compared to Euro 2.4 million in the last year's period). Earnings per share were at Euro 0.08 in comparison to Euro 0.05 in the same period of the previous year. biolitec AG's major revenues were generated in Europe and North America. With Euro 3.5 million, sales in North America increased of +3% compared to previous year's level. European sales amounted to Euro 3.3 million (previous year: Euro 3 million). Our foreign subsidiaries, especially in the Arabian region and Asia, contribute increasingly to overall results and showed pleasingly high growth rates of +102% to Euro 2.2 million in comparison to the first quarter of the previous year. biolitec's medium-term goal is to increase these markets' proportion of sales up to one third and thus lay the basis of further growth adapted to the world market situation. Sales in the business segment Meditec amounted to Euro 8.47 million in the first quarter of the fiscal year 2011/2012; in the Pharma segment, the sales increased by 20% to nearly Euro 0.5 million. On May 31st 2011, biolitec announced sales of Euro 26.1 million for the first three quarters of the fiscal year 2010/2011 (previous year: Euro 21.8 million), which was an increase by 19%. Unfortunately, the publication of the annual financial statement 2010/2011 has been postponed in the following until today due to increased auditing work. For that reason, biolitec has decided to publish the first quarter of 2011/2012 even without available audit for the annual financial statement 2010/11 to inform shareholders about the situation of the company. In the meantime, biolitec has planned to transfer its registered office to Austria. Due to this transfer to Austria and the concomitant downstream merger into the Entry Standard, biolitec AG will be able to profit from fiscal optimization possibilities such as the Austrian group taxation, but will also move closer to growing future markets in Eastern Europe. An extraordinary general meeting on this topic is being prepared. For the current business year biolitec expect continued growth. 15.06.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Germany Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden